NASDAQ
ADMA Biologics, Inc. (ADMA) reported revenue of $510.17M and net income of $146.93M for FY 2025. The gross profit margin is 57.4% with a net profit margin of 28.8%.
Financial data for ADMA
19.63% YoY
25.67% YoY
27.06% YoY
Annual Income Statement for ADMA
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $510M | $426M | $258M | $154M | $81M |
| Cost of Revenue | $217M | $207M | $169M | $119M | $80M |
| Gross Profit | $293M | $220M | $89M | $35M | $1M |
| Operating Expenses | $101M | $81M | $67M | $75M | $60M |
| Operating Income | $191M | $139M | $22M | -$39M | -$58M |
| Net Income | $147M | $198M | -$28M | -$66M | -$72M |
| EPS | $0.62 | $0.85 | $-0.13 | $-0.43 | $-0.61 |
| EBITDA | $198M | $148M | $5M | -$40M | -$53M |
No price data available for this timeframe.